Company News

Share this article:

GlaxoSmithKline may owe the IRS nearly $2 billion in back taxes, interest and penalties, the Wall Street Journal reported Friday. The back taxes are a result of “earnings stripping,” a practice multinational companies use to “reduce taxes by claiming interest deductions for payments to a related unit overseas,” the WSJ reported. GSK paid the IRS $3.4 billion in 2006, to end litigation over whether its US operations paid its UK-based parent too much for drugs, which lowered its taxes.

 

Johnson & Johnson announced that it will acquire Cougar Biotechnology for $893 million, or $43 per share. Based in Los Angeles, Cougar Biotech is primarily focused on oncology products, and is currently developing several products for prostate cancer, breast cancer, and other kinds of cancer. Although Cougar doesn't currently have any products on the market, J&J hopes the company's lead candidate, abiraterone acetate (CB7630), now in phase III trials for prostate cancer – will gain an FDA approval by late 2010. Cougar will become part of J&J's Ortho Biotech Oncology Research & Development division.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.